←Back to Expert Scholars
Translational Medicine / 转化医学Milestone IO Approvals
F. Stephen Hodi
MD
🏢Dana-Farber Cancer Institute🌐USA
Director, Melanoma Center and Center for Immuno-Oncology
110
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
F. Stephen Hodi led the MDX010-020 phase III trial that demonstrated ipilimumab survival benefit in advanced melanoma and led to the first checkpoint inhibitor FDA approval in 2011. He directs the Melanoma Center and Center for Immuno-Oncology at Dana-Farber.
Share:
🧪Research Fields 研究领域
ipilimumab melanoma
MDX010-020 trial
first CTLA-4 approval
melanoma IO
combination checkpoint
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 F. Stephen Hodi 的研究动态
Follow F. Stephen Hodi's research updates
留下邮箱，当我们发布与 F. Stephen Hodi（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment